Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemiase: a report on behalf of the Cnronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
SourceBritish Journal of Haematology, 110, (2000), pp. 620-630
Article / Letter to editor
Display more detailsDisplay less details
Physical Organic Chemistry
British Journal of Haematology
SubjectEuropean evaluation of intensive antileukemic therapy for patients with myelodysplastic syndrome (MDS) CRIANT: clonal remission after intensive antileukemic therapy (Biomed-2 1995); Hematopoiesis and stem cell transplantation
Allogeneic stem cell transplantation from an HLA-identical sibling donor is a curative treatment option for a young patient with myelodysplastic syndrome, limited by age and lack of sibling donors. Alternative stem ceel sources have been used more recently such as unrelated donors, non-identical family members or autologous transplants. This analysis of 11378 transplants reported tho the EBMT adresses the outcome of the varying procedures according to the known risk factors. The estimated disease free survival (DES) and estimated relapse risk at 3 years were both 36% for 885 patients transplantated with stem cells from matched siblings. In the multivariate analysis, age and stage of disease had significantly lower risk of relapse than patients transplanted at more advanced stages.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.